BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. announced today that it will host a Webinar concerning its emerging siRNA therapeutics programs and siRNA drug delivery technology. Steven C. Quay, M.D., Ph.D., Chairman, President and CEO will present at the event.
What: RNAi webinar on the science and business of RNAi therapeutics followed by a Q&A session. Questions may be emailed in advance to rnaiwebinar@nastech.com or during the event through the webinar interface When: Thursday, November 9, 2006, from 10:30-11:15 AM U.S. East Coast time How: Live over the Internet FREE via a simple advanced registration at http://www.talkpoint.com/viewer/starthere.asp?Pres=114985 Where: Webinar will be available at http://www.talkpoint.com/viewer/presentation.asp once you are registered
If you are unable to participate during the live RNAi webinar webcast, an archive and replay will be available for 30 days via Nastech's website at http://investor.nastech.com/phoenix.zhtml?c=83674&p=irol-calendar
During the webinar, Dr. Quay will provide an overview of the exciting science behind RNAi and discuss the Company's rheumatoid arthritis and influence therapeutics programs as well as the Company's molecular biology based drug delivery technology.
Key events in Nastech's RNAi program to date: 9/26/06 - Nastech Receives $1.9 Million National Institute of Health-R01 Grant for Development of RNAi Therapeutics to Prevent and Treat Influenza 8/29/06 - Nastech Awarded Development Grant for RNAi Therapeutics to Prevent and Treat Influenza, including Avian Flu 3/16/06 - Nastech Presents Successful In Vitro and In Vivo Results with Its RNAi Therapeutics Program for Influenza 2/23/06 - Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea 11/17/05 - Nastech Presents Positive Results on RNA Interference Program for Treatment of Rheumatoid Arthritis at the American College of Rheumatology Annual Scientific Meeting 7/20/05 - Alnylam Grants Nastech a License to Develop RNAi Therapeutics Against TNF-alpha 4/5/05 - Nastech Announces RNAi Therapeutics-Based Rheumatoid Arthritis Clinical Study Collaboration 4/5/05 - Nastech Presents Promising In Vivo Research Findings with RNAi- Based Therapeutics for Rheumatoid Arthritis at the 2005 American Society for Biochemistry and Molecular Biology Annual Meeting 2/2/04 - Nastech Obtains a Non-exclusive License from the Carnegie Institute of Washington, D.C. to the Fire et al Patents and Patent Applications Titled "Genetic Inhibition by Double- Stranded RNA" (including U.S. Patent # 6,506,559 B1) About Nastech
Nastech is a pharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, diabetes, obesity, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
CONTACTS: Nastech Ed Bell Senior Investor Relations Manager (425) 908-3639 ir@nastech.com Noonan Russo Matthew Haines (Investors/Media) (212) 845-4235
Nastech Pharmaceutical Company Inc.CONTACT: Ed Bell, Senior Investor Relations Manager, Nastech,+1-425-908-3639, ir@nastech.com; or Noonan Russo, Matthew Haines,Investors/Media, +1-212-845-4235
